Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market by Product, Application, and Geography - Forecast and Analysis 2023-2027

Published: Feb 2023 Pages: 166 SKU: IRTNTR73132

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Forecast 2023-20207

The diffuse large B-cell lymphoma (DLBCL) therapeutics market is estimated to increase by USD 2,061.88 million between 2022 and 2027. The size of the market is forecast to grow at a CAGR of 7.96%. The growth of the market depends on several factors, including the growing geriatric population, increasing incidence, and increasing approval of therapeutics for patients with relapsed or refractory DLBCL. 

What will be the size of the Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Dynamics

The increasing approval of therapeutics for patients with relapsed or refractory DLBCL is notably driving the market growth, although factors such as the high cost of the treatment may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Driver

The increasing approval of therapeutics for patients with relapsed or refractory DLBCL is notably driving market growth. Market players are focusing on regulatory approvals for therapeutics for patients with relapsed or refractory DLBCL, which is expected to fuel market growth. For instance, in February 2021, Bristol Myers Squibb, a pharmaceutical company, received approval for lisocabtagene maraleucel (liso-cel, Breyanzi), chimeric antigen receptor (CAR) T-cell therapy, indicated for diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B, in patients who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

Similarly, in November 2020, ADC Therapeutics SA, a late clinical-stage biotechnology company, announced that its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) had been accepted by the US Food and Drug Administration (FDA). Lloncastuximab tesirine (Lonca) is being developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Hence, such developments will drive the growth of the global diffuse large B-Cell lymphoma therapeutics market during the forecast period.

Significant Trend

Technological advances are an emerging trend in market growth. Companies are focusing on developing new technologies and innovative therapies that can overcome the current challenges in the treatment of various cancers, including DLBCL. Currently, many technological advances, such as chimeric antigen receptor (CAR) T-cell therapy, gene therapy, companion diagnostics, and personalized medicines, are being developed at a very rapid pace.

Technological advances increase the efficacy of products and invent highly effective drugs for the treatment of various diseases. Through such technological advances, industry-focused players such as Novartis and Gilead and diversified players such as F. Hoffmann-La Roche are focusing on CAR T-cell therapy and gene therapy. These new therapy areas are more effective and reduce the efforts in the treatment. Therefore, factors like these will fuel the growth of the global diffuse large B-Cell lymphoma therapeutics market during the forecast period.

Major Challenge

The high cost of DLBCL treatment is a major challenge impeding the market growth. The high treatment cost associated with cancer is the most important cause of concern for patients. Drugs such as vincristine, doxorubicin, and either prednisone or bortezomib may help some patients with advanced DLBCL, which are associated with high costs. Chemotherapy also needs to be continued for a substantial period for the long-term survival of the patient, which further adds to the cost of the treatment. Also, as per the NCBI, the probability of recurrent or relapsed DLBCL is up to 30% of cases worldwide. Hence, treating advanced-stage NHL, particularly this treatment, becomes expensive. 

Furthermore, the cost of biologics available for the treatment of DLBCL THERAPEUTICS is high. Moreover, the inadequate distribution network of drugs in underdeveloped and developing economies is resulting in high distribution costs, which increases the cost of DLBCL therapeutics further. Although developed markets such as the US, Canada, the UK, and Germany have strong healthcare systems, the prices of the available drugs are substantially high. Therefore, factors like these will hinder the growth of the global diffuse large B-Cell lymphoma therapeutics market during the forecast period.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market companies?

companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Amgen Inc. - The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics. The key offerings of the company include diffuse large B-cell lymphoma therapeutics. 

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

  • AbbVie Inc.
  • ADC Therapeutics SA
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb Co.
  • Celltrion Healthcare Co. Ltd.
  • CTI BioPharma Corp.
  • Erytech Pharma SA
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Market?

The market share growth by the hospital pharmacy segment will be significant during the forecast period. Hospital pharmacies play an important role in the management, as they are responsible for the storage, preparation, and dispensing of DLBCL therapeutics to patients. DLBCL therapeutics are often administered in a hospital or clinical setting, and hospital pharmacists are typically involved in the management of these treatments, including monitoring patients for adverse effects and drug interactions. 

Get a glance at the market contribution of various segments Request a PDF Sample

The hospital pharmacy segment was valued at USD 1,438.58 million in 2017 and continued to grow until 2021.  The hospital pharmacy segment is a significant part of the DLBCL therapeutics market, as many of these treatments are administered in a hospital or clinical setting. Hospital pharmacies are responsible for ensuring the safe and effective use of DLBCL therapeutics, which includes proper storage, preparation, and dispensing of these medications to patients. They also play a crucial role in monitoring patients for adverse effects and drug interactions, providing education to patients, and working closely with healthcare providers to ensure the best possible care for patients with DLBCL. Hence, owing to such advantages the DLBCL therapeutics market segment will register growth during the forecast period.

Which are the Key Regions for the Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The growth of the market in this region is primarily driven by the sales of approved therapeutics for the treatment of various subtypes of NHL and the increasing prevalence of various cancer types, including DLBCL. According to the National Program of Cancer Registries (NPCR), which is carried out by the Centers for Disease Control and Prevention (CDC), more than 28.5 million invasive cancer cases have been diagnosed in the last two decades. NHL is the eighth-most prevalent type of cancer in the US, which is the reason for the country being a major contributor to the market in North America. According to the CDC, in 2021, the prevalence of DLBCL in the US was 22% per 100,000 people. Such a high prevalence of the disease demands advanced and specialized treatment options. Targeted therapies, such as VELCADE and CALQUENCE, have the potential to meet this requirement. Hence, the high prevalence of DLBCL is expected to drive the growth of the market in North America during the forecast period. 

Although the US has various approved therapies for the treatment of DLBCL, the cost of most of these target-specific drugs is high. The high cost of these drugs is a potential challenge for the market, and patient assistance programs offset this challenge to a great extent. For instance, Johnson and Johnson provides a patient assistance program. Under this program, the company provides eligible patients with free prescription medicines. The assistance includes contacting patients' insurance providers to help patients understand their coverage. Thus, the increasing prevalence of DLBCL and the availability of targeted therapies and patient assistance programs are expected to support the growth of the DLBCL therapeutics market in North America during the forecast period.

Market Analyst Overview

The market is witnessing significant advancements driven by patient awareness, collaborative initiatives, and evolving standards of care. Biomarker discovery and immunotherapy innovations are revolutionizing treatment approaches. Incidence rates are spurring healthcare infrastructure development, enhancing access to novel drugs in outpatient settings. Collaborative clinical trials and patient-centric care models are shaping treatment paradigms. Diagnostic imaging advances aid in early diagnosis, while healthcare digitalization improves patient management. DLBCL prevalence underscores the importance of genetic and molecular profiling for personalized treatment strategies. Conventional RCHOP therapy remains pivotal, alongside diagnostic devices, radiation therapy equipment, and surgical instruments. The market's trajectory reflects a concerted effort towards improving outcomes and addressing the evolving needs of DLBCL patients.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Product Outlook (USD Million, 2017 - 2027)
    • Small molecules
    • Biologics
  • Application Outlook (USD Million, 2017 - 2027)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Others
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
      • Vietnam
      • Others
    • Rest of World
      • Saudi Arabia
      • South Africa
      • Brazil
      • Others

Market Scope

Report Coverage

Details

Page number

166

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 7.96%

Market growth 2023-2027

USD 2,061.88 million

Market structure

Fragmented

YoY growth 2022-2023(%)

7.13

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 46%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Market dynamics

Parent market analysis, Market forecasting, market growth and trends, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. 

Customization purview

If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 - 2021 ($ million)
    • 4.2 Application Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Application Segment 2017 - 2021 ($ million)
    • 4.3 Product Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Product Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Application

    • 6.1 Market segments
      • Exhibit 30: Chart on Application - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Application - Market share 2022-2027 (%)
    • 6.2 Comparison by Application
      • Exhibit 32: Chart on Comparison by Application
      • Exhibit 33: Data Table on Comparison by Application
    • 6.3 Hospital pharmacy - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
    • 6.4 Retail pharmacy - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
    • 6.5 Online pharmacy - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)
    • 6.6 Others - Market size and forecast 2022-2027
      • Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 6.7 Market opportunity by Application
      • Exhibit 50: Market opportunity by Application ($ million)
      • Exhibit 51: Data Table on Market opportunity by Application ($ million)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 52: Chart on Product - Market share 2022-2027 (%)
      • Exhibit 53: Data Table on Product - Market share 2022-2027 (%)
    • 7.2 Comparison by Product
      • Exhibit 54: Chart on Comparison by Product
      • Exhibit 55: Data Table on Comparison by Product
    • 7.3 Small molecules - Market size and forecast 2022-2027
      • Exhibit 56: Chart on Small molecules - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Data Table on Small molecules - Market size and forecast 2022-2027 ($ million)
      • Exhibit 58: Chart on Small molecules - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on Small molecules - Year-over-year growth 2022-2027 (%)
    • 7.4 Biologics - Market size and forecast 2022-2027
      • Exhibit 60: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 62: Chart on Biologics - Year-over-year growth 2022-2027 (%)
      • Exhibit 63: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Product
      • Exhibit 64: Market opportunity by Product ($ million)
      • Exhibit 65: Data Table on Market opportunity by Product ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 UK - Market size and forecast 2022-2027
      • Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.10 Canada - Market size and forecast 2022-2027
      • Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.11 China - Market size and forecast 2022-2027
      • Exhibit 103: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 104: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 105: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 106: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ million)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 115: AbbVie Inc. - Overview
              • Exhibit 116: AbbVie Inc. - Product / Service
              • Exhibit 117: AbbVie Inc. - Key news
              • Exhibit 118: AbbVie Inc. - Key offerings
            • 12.4 Amgen Inc.
              • Exhibit 119: Amgen Inc. - Overview
              • Exhibit 120: Amgen Inc. - Product / Service
              • Exhibit 121: Amgen Inc. - Key offerings
            • 12.5 Bayer AG
              • Exhibit 122: Bayer AG - Overview
              • Exhibit 123: Bayer AG - Business segments
              • Exhibit 124: Bayer AG - Key news
              • Exhibit 125: Bayer AG - Key offerings
              • Exhibit 126: Bayer AG - Segment focus
            • 12.6 BeiGene Ltd.
              • Exhibit 127: BeiGene Ltd. - Overview
              • Exhibit 128: BeiGene Ltd. - Business segments
              • Exhibit 129: BeiGene Ltd. - Key offerings
              • Exhibit 130: BeiGene Ltd. - Segment focus
            • 12.7 Bristol Myers Squibb Co.
              • Exhibit 131: Bristol Myers Squibb Co. - Overview
              • Exhibit 132: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 133: Bristol Myers Squibb Co. - Key news
              • Exhibit 134: Bristol Myers Squibb Co. - Key offerings
            • 12.8 Celltrion Healthcare Co. Ltd.
              • Exhibit 135: Celltrion Healthcare Co. Ltd. - Overview
              • Exhibit 136: Celltrion Healthcare Co. Ltd. - Product / Service
              • Exhibit 137: Celltrion Healthcare Co. Ltd. - Key offerings
            • 12.9 CTI BioPharma Corp.
              • Exhibit 138: CTI BioPharma Corp. - Overview
              • Exhibit 139: CTI BioPharma Corp. - Product / Service
              • Exhibit 140: CTI BioPharma Corp. - Key offerings
            • 12.10 Erytech Pharma SA
              • Exhibit 141: Erytech Pharma SA - Overview
              • Exhibit 142: Erytech Pharma SA - Product / Service
              • Exhibit 143: Erytech Pharma SA - Key offerings
            • 12.11 F. Hoffmann La Roche Ltd.
              • Exhibit 144: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 145: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 146: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 147: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 148: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.12 GlaxoSmithKline Plc
              • Exhibit 149: GlaxoSmithKline Plc - Overview
              • Exhibit 150: GlaxoSmithKline Plc - Business segments
              • Exhibit 151: GlaxoSmithKline Plc - Key offerings
              • Exhibit 152: GlaxoSmithKline Plc - Segment focus
            • 12.13 Johnson and Johnson
              • Exhibit 153: Johnson and Johnson - Overview
              • Exhibit 154: Johnson and Johnson - Business segments
              • Exhibit 155: Johnson and Johnson - Key news
              • Exhibit 156: Johnson and Johnson - Key offerings
              • Exhibit 157: Johnson and Johnson - Segment focus
            • 12.14 Merck and Co. Inc.
              • Exhibit 158: Merck and Co. Inc. - Overview
              • Exhibit 159: Merck and Co. Inc. - Business segments
              • Exhibit 160: Merck and Co. Inc. - Key news
              • Exhibit 161: Merck and Co. Inc. - Key offerings
              • Exhibit 162: Merck and Co. Inc. - Segment focus
            • 12.15 Novartis AG
              • Exhibit 163: Novartis AG - Overview
              • Exhibit 164: Novartis AG - Business segments
              • Exhibit 165: Novartis AG - Key offerings
              • Exhibit 166: Novartis AG - Segment focus
            • 12.16 Pfizer Inc.
              • Exhibit 167: Pfizer Inc. - Overview
              • Exhibit 168: Pfizer Inc. - Product / Service
              • Exhibit 169: Pfizer Inc. - Key news
              • Exhibit 170: Pfizer Inc. - Key offerings
            • 12.17 Spectrum Pharmaceuticals Inc.
              • Exhibit 171: Spectrum Pharmaceuticals Inc. - Overview
              • Exhibit 172: Spectrum Pharmaceuticals Inc. - Product / Service
              • Exhibit 173: Spectrum Pharmaceuticals Inc. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 174: Inclusions checklist
                • Exhibit 175: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 176: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 177: Research methodology
                • Exhibit 178: Validation techniques employed for market sizing
                • Exhibit 179: Information sources
              • 13.5 List of abbreviations
                • Exhibit 180: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              diffuse large b-cell lymphoma (dlbcl) therapeutics market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis